...
首页> 外文期刊>Kidney and blood pressure research >Detecting Proteomic Indicators to Distinguish Diabetic Nephropathy from Hypertensive Nephrosclerosis by Integrating Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging with High-Mass Accuracy Mass Spectrometry
【24h】

Detecting Proteomic Indicators to Distinguish Diabetic Nephropathy from Hypertensive Nephrosclerosis by Integrating Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging with High-Mass Accuracy Mass Spectrometry

机译:通过将基质辅助激光解吸/电离成像与高质量精度质谱分解成像,检测蛋白质组学指标以区分高血压肾功能粥样硬化病变

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Diabetic nephropathy (DN) and hypertensive nephrosclerosis (HN) represent the most common causes of chronic kidney disease (CKD) and many patients progress to end-stage renal disease. Patients are treated primarily through the management of cardiovascular risk factors and hypertension; however patients with HN have a more favorable outcome. A noninvasive clinical approach to separate these two entities, especially in hypertensive patients who also have diabetes, would allow for targeted treatment and more appropriate resource allocation to those patients at the highest risk of CKD progression. Methods: In this preliminary study, high-spatial-resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) was integrated with high-mass accuracy MALDI-FTICR-MS and nLC-ESI-MS/MS analysis in order to detect tissue proteins within kidney biopsies to discriminate cases of DN ( n = 9) from cases of HN ( n = 9). Results: Differences in the tryptic peptide profiles of the 2 groups could clearly be detected, with these becoming even more evident in the more severe histological classes, even if this was not evident with routine histology. In particular, 4 putative proteins were detected and had a higher signal intensity within regions of DN tissue with extensive sclerosis or fibrosis. Among these, 2 proteins (PGRMC1 and CO3) had a signal intensity that increased at the latter stages of the disease and may be associated with progression. Discussion/Conclusion: This preliminary study represents a valuable starting point for a future study employing a larger cohort of patients to develop sensitive and specific protein biomarkers that could reliably differentiate between diabetic and hypertensive causes of CKD to allow for improved diagnosis, fewer biopsy procedures, and refined treatment approaches for clinicians.
机译:介绍:糖尿病肾病(DN)和高血压肾粥样硬化(HN)代表慢性肾病(CKD)的最常见原因,以及许多患者对终末期肾病的进展。患者主要通过管理心血管危险因素和高血压治疗;然而,HN患者具有更有利的结果。一种非侵入性的临床方法,将这两个实体分开,特别是在患有糖尿病的高血压患者中,将允许有针对性的治疗和更适当的资源分配,以最高的CKD进展的患者。方法:在该初步研究中,高空间分辨率基质辅助激光解吸/电离(MARDI)质谱成像(MSI)与高质量精度MALDI-FTICR-MS和NLC-ESI-MS / MS分析集成在内为了检测肾脏活检中的组织蛋白,以从HN(n = 9)的情况下区分DN(n = 9)的病例。结果:可以清楚地检测到2组的胰蛋白酶肽谱的差异,并且在更严重的组织学课程中,即使这对常规组织学不明显,这些差异也变得更加明显。特别地,检测到4个推定蛋白质,并且在DN组织区域内具有较高的信号强度,具有广泛的硬化或纤维化。其中,2种蛋白质(PGRMC1和CO3)的信号强度在疾病的后一级增加,并且可能与进展相关。讨论/结论:这项初步研究代表了未来研究的有价值的起点,该研究可以使用较大的患者队列开发敏感性和特异性蛋白质生物标志物,这些蛋白质生物标志物可以可靠地区分CKD的糖尿病和高血压原因,以便改善诊断,更少的活组织检查程序,更少的活组织检查程序,临床医生精制治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号